Thursday, July 13, 2023 3:37:04 PM
Doc,
The only time I believe the regulators ever comment on anything involving a company beyond their actions on official documents is if the company misrepresents what they're being told by, or doing with, the regulators. They simply don't update stockholders and they won't be intimidated by them.
For those who remember DNDN, the shareholders tried all sorts of things to push the approval of Provenge. When DNDN met their demand it was approved, but all the threats to go to Congress, the Supreme Court, etc. had no apparent effect on the FDA and frankly I wouldn't be surprised if it slowed them down.
NWBO has been more secretive about their plans than most, but really not all biotech's, very few are so open with investors that at least some investors don't complain. When a company is very open, like CVM, I urge caution with believing what they're saying.
The end of this month, or early next, we'll get a quarterly, it at least provides an opportunity for the company to update the shareholders. Let's hope they take it and give us some guidance for at least what the remainder of the year should hold.
Gary
The only time I believe the regulators ever comment on anything involving a company beyond their actions on official documents is if the company misrepresents what they're being told by, or doing with, the regulators. They simply don't update stockholders and they won't be intimidated by them.
For those who remember DNDN, the shareholders tried all sorts of things to push the approval of Provenge. When DNDN met their demand it was approved, but all the threats to go to Congress, the Supreme Court, etc. had no apparent effect on the FDA and frankly I wouldn't be surprised if it slowed them down.
NWBO has been more secretive about their plans than most, but really not all biotech's, very few are so open with investors that at least some investors don't complain. When a company is very open, like CVM, I urge caution with believing what they're saying.
The end of this month, or early next, we'll get a quarterly, it at least provides an opportunity for the company to update the shareholders. Let's hope they take it and give us some guidance for at least what the remainder of the year should hold.
Gary
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
